ClinicalTrials.gg
CompletedNCT00691184Updated Jun 5, 2008

Safety and Pharmacokinetics of Terbinafine Hydrogen Chloride (HCl) Nail Lacquer in Patients With Onychomycosis

A Phase 1 interventional study of Placebo and Terbinafine Hydrochloride in Onychomycosis/Onycholysis and Tinea Pedis, sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.). Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-06-05.

Sponsored by NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing terbinafine in Onychomycosis — 1 open to participants now, 2 under way, 1 of them phase 3. Terbinafine · Onychomycosis.

Enrollment
13th of 19
56 · median 100
Started
2005
the only one that year
Phase 1
3 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
1 of 20
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)

Among the 20 studies testing terbinafine in Onychomycosis, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2005, is one of 3 in phase 1, and was the 6th registered.

Onychomycosis

158 studies on the registry are indexed under Onychomycosis; 16 are open to participants now.

Browse Onychomycosis studies →

Open to participants now

1 of the 20 studies testing terbinafine in Onychomycosis is open now. Recruiting first, the newest first:

About terbinafine

Terbinafine: first FDA approval 1992 (LAMISIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 9 Onychomycosis studies recruiting now, 3 set no upper age limit and 5 stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing terbinafine in Onychomycosis, or all of them as a file.
02

Study summary

In this study, the safety and pharmacokinetics of 10 % terbinafine hydrogen chloride (HCl) nail lacquer wre investigated by comparison with vehicle control and 1% terbinafine cream

Read the detailed description

This was a double-blind, randomized, parallel-design, placebo-controlled Phase 1 study comparing 10% Terbinafine HCl Nail Lacquer vs. Placebo Nail Lacquer (i.e., vehicle control). For comparative purposes, the study also included a contemporaneous assessment of 1% Lamisil® Cream (1% terbinafine HCl) and Lamisil® Tablets (terbinafine HCl labeled as 250 mg of terbinafine).

Forty (40) onychomycosis (Groups 1 and 2) and 16 tinea pedis (Group 3) patients were enrolled at 3 study centers. In Group 1, 10% Terbinafine HCl Nail Lacquer, and, in Group 2, its vehicle (0% terbinafine HCl), were applied topically by brushing on a dose volume of approximately 10 μL per nail twice daily for 28 days to each toenail and to 5 mm of adjacent skin. The patients visited the study center on Days 3, 7, 14, 21, and 28 for assessments of clinical signs and to obtain blood samples. In addition, a 24-hour urine sample was collected and assessed on Day 28 and Day 35. Fifty six (56) patients (20 in Group 1, 20 in Group 2, and 16 in Group 3) received a single oral dose of a 250 mg Lamisil® Tablet after a 7-day washout period.

For comparative purposes, the study also evaluated the local and systemic safety, and plasma levels of terbinafine, and its 3 major metabolites (i.e., desmethyl terbinafine, carboxybutyl terbinafine, and desmethyl carboxybutyl terbinafine) following administration of 1% Lamisil® Cream in comparison with 10% Terbinafine HCl Nail Lacquer. In Group 3, approximately 0.5 g of 1% Lamisil® Cream was applied twice a day for 7 days to the area of the foot affected with tinea pedis. The patients visited the study center on Day 3 and on Day 7 for assessments of clinical signs and collection of blood samples. A 24-hour urine sample was collected and assessed on Day 7 and Day 14.

03

Conditions studied

  • Onychomycosis/Onycholysis and Tinea Pedis

Keywords

  • Onychomycosis, Toenail fungal infection, Terbinafine HCl, Pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients were required to meet all of the following criteria in order to be eligible for entry in the study:

  • Were between 18 and 70 years of age, of any race and of either sex;
  • Were in good general health as confirmed by a medical history and brief physical examination;
  • Groups 1 and 2, presented with clinically diagnosed stable or exacerbating onychomycosis with more than 25 % involvement of one great toenail;
  • For Group 3, had mild tinea pedis (mild tinea pedis was defined as mild erythema, mild scaling, cracking or fissuring, and mild burning or pruritus);
  • For Groups 1 and 2, had at least five toenails with onycholysis;
  • For Groups 1 and 2, a positive calcofluor (KOH) exam must have been obtained during Visit 1 from specimens taken from the affected great toenail;
  • Signed a statement of ;
  • Were able to understand the requirements of the study, abide by the restrictions, and return for all of the required examinations;
  • If female, met one of the following criteria: (a) had been for at least one year, or (b) had a hysterectomy or tubal ligation, or (c) was using oral/systemic or an intrauterine device at least 28 days prior to study entry and throughout the study, or (d) agreed to use spermicide in combination with barrier methods of contraception throughout the study;
  • Had 10 toes with nails that could be clipped to provide nail samples.

Exclusion criteria

Exclusion Criteria:

Any of the following excluded a patient from participating in the study:

  • Any missing toes;
  • Known to terbinafine or any of the in the nail lacquer;
  • Vital signs measurement that were clinically significantly outside the normal limits;
  • Liver function test values more than two times the or other clinical laboratory values, which were clinically significantly outside normal limits;
  • Receipt of terbinafine tablets within 12 months or terbinafine cream or solution within six months prior to screening;
  • Participation in a clinical trial for the systemic treatment of onychomycosis within the previous two months;
  • Current treatment with rifampin, phenobarbital, phenytoin, carbamazepine, terfenadine, or digoxin;
  • Prior treatment with an drug within one month prior to study start;
  • Diagnosis of psoriasis or history of psoriasis;
  • Diagnosis of a serious concurrent disease that might prevent completion of the trial;
  • Pregnancy (confirmed by pregnancy test), or plan to become pregnant within the study period or nursing;
  • Inability to read, understand, or sign the form or the patient instructions for applying and removing the study formulations;
  • Inability to apply the study medication;
  • Onychomycosis patient unwilling to provide nail clippings;
  • Inability to provide adequate blood sample;
  • Use of any nail polish products or other nail cosmetic products within seven days prior to the start of treatment, or unwilling to discontinue use of these products during the course of this study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Group 1

    0% Terbinafine HCl Nail Lacquer for 28 days.

    Drug: Placebo

  • Experimental
    Group 2

    10% Terbinafine HCl Nail Lacquer.

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group 3

    1% Lamisil® Cream

    Drug: Terbinafine Hydrochloride

  • Active comparator
    Group 4

    Dose of 250 mg Lamisil® Tablets (Groups 1,2,3) at end of study.

    Drug: Terbinafine

Interventions

  • DrugPlacebo

    0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.

  • 10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.

  • 1% Terbinafine Hydrochloride Cream, twice a day for 7 days.

    Also known as: Lamisil® Cream, 1%

  • Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.

    Also known as: Lamisil, 250mg tablet

06

What researchers measure

Primary outcomes

  1. The primary safety objective was to determine the safety of 10% Terbinafine HCl Nail Lacquer by assessing local and systemic adverse experiences, changes in vital signs, clinical laboratory test results, physical examinations, and electrocardiogram (ECG)

    Time frame: 28 Days

Secondary outcomes

  1. To determine plasma levels of terbinafine and its metabolites after administration of 10% Terbinafine HCl Nail Lacquer to toenails, 1% Lamisil® Cream to the infected (i.e., tinea pedis) area of the foot and a single Lamisil® Tablet (250 mg) on Day 35.

    Time frame: 3, 7, 14, 21 and 28 days and Day 35

07

Study locations

1 site
  • TKL Research Inc.
    Paramus, New Jersey 07652, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Jun 2005 and a completion of Dec 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2008
First posted
Jun 5, 2008
Start
Feb 2005
Primary completionActual
Jun 2005
CompletionActual
Dec 2005
Last update
Jun 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00691184
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
First posted
Jun 5, 2008
Start date
Feb 2005
Primary completion
Jun 2005
Completion
Dec 2005
Last update
Jun 5, 2008

Study contacts

Ming Q Lu, MD., Ph.D.
study director · NexMed (U.S.A.), Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Terbinafine

Start the discussion